|
|
HMBA |
|
Vaxjo ID |
328 |
|
Vaccine Adjuvant Name |
HMBA |
|
Alternative Names |
Hexamethylene bisacetamide |
|
Description |
Hexamethylene bisacetamide (HMBA) is an anti-proliferative agent, a hybrid bipolar compound developed for its ability to induce terminal differentiation of transformed cells. It has also been shown to trigger HIV transcription from latently infected cells. The paper investigates its effect on the immune response, finding that it acts as an adjuvant during intracellular bacterial infections by inducing Type I IFN through STING. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
anti-proliferative agent hexamethylene bisacetamide (HMBA) belongs to a class of hybrid bipolar compounds |
|
Function |
HMBA significantly improved IL-12p70 production from CD14+ monocytes during infection partly via the induction of type I IFN in these cells, which primed an increased transcription of the p35 subunit of IL-12p70 during infection. HMBA also increased early type I IFN transcription in human monocytic and epithelial cell lines, but this was surprisingly independent of its previously reported effects on positive transcription elongation factor b and HMBA inducible protein-1. |
| References |
Gamage et al., 2017: Gamage AM, Lee KO, Gan YH. Anti-Cancer Drug HMBA Acts as an Adjuvant during Intracellular Bacterial Infections by Inducing Type I IFN through STING. Journal of immunology (Baltimore, Md. : 1950). 2017; 199(7); 2491-2502. [PubMed: 28827286].
|
|
